Abstract: A surgical stapling device (10) includes a replaceable cartridge assembly (44) having knife assembly (80) and an anvil assembly (42) including a cutting plate (52). The cutting plate (52) is configured be durable to maintain performance of the stapling device (10) over multiple firings.

Abstract: A surgical stapling device includes an anvil assembly and a replaceable cartridge assembly. The cartridge assembly includes a knife blade and upper and lower alignment pins for retaining tissue between anvil and cartridge assemblies to ensure that the knife blade cuts cleanly through tissue. The cartridge assembly includes a cartridge body having guide structure for guiding the cartridge assembly onto a clamp slide assembly of the stapling device.

Abstract: A surgical stapling device includes a tool assembly having a U-shaped frame, an anvil assembly, and a cartridge assembly. The cartridge assembly includes a knife that is movable between retracted and advanced positions. The anvil assembly is supported on the distal frame portion and includes a cutting plate and an anvil plate. The cutting plate is positioned between the distal frame portion and the anvil plate and is engaged by the knife as the knife moves from the retracted position towards the advanced position. The cutting plate is formed of a material that deforms locally and structurally upon engagement with the knife.

Abstract: A surgical stapling device includes a tool assembly having a U-shaped frame, an anvil assembly, and a cartridge assembly. The U-shaped frame has a proximal transverse portion, a longitudinal portion, and a distal transverse portion. The distal transverse portion and the proximal transverse of the U-shaped frame and the cartridge assembly have a common shape including a first linear portion defining a first axis, a second linear portion defining a second axis, and a third linear portion defining a third axis, the first axis being transverse to the longitudinal axis of the elongate body. In embodiments, a first radius of curvature is defined between the first linear portion and the second linear portion such that the first axis and the second axis define an angle ?, and a second radius of curvature is defined between the second linear portion and the third linear portion such that the second axis and the third axis define an angle ?.

Abstract: A surgical stapling device includes a removable or releasable cartridge assembly. The surgical stapling device and the cartridge assembly include engagement members for releasably securing a thrust bar of the stapling device to a knife assembly of the cartridge assembly. The stapling device also includes structure to prevent the knife assembly from being disengaged from a cartridge body of the cartridge assembly and for obstructing advancement of the knife assembly within the cartridge body after the stapling device has been fired.

Abstract: A surgical stapling device includes an anvil assembly and a replaceable cartridge assembly. The cartridge assembly includes a knife blade and upper and lower alignment pins for retaining tissue between anvil and cartridge assemblies to ensure that the knife blade cuts cleanly through tissue. The cartridge assembly includes a cartridge body having guide structure for guiding the cartridge assembly onto a clamp slide assembly of the stapling device.

Abstract: A curved cartridge assembly of a surgical stapler includes a staple cartridge, an alignment pin received in the staple cartridge and configured to engage an opening in an anvil assembly, and a shipping cap configured to detachably couple to the staple cartridge. The shipping cap has is engaged with the distal end portion of the alignment pin to resist translation of the alignment pin. With the cartridge assembly loaded into the surgical stapler, upon releasing the shipping cap from the staple cartridge the alignment pin translates into engagement with the opening in the anvil assembly.

Abstract: A surgical stapling instrument includes an elongate body portion defining a longitudinal axis, and an end effector supported on a distal portion of the elongated body portion. The end effector includes a housing having a base portion and a jaw portion, an anvil assembly supported on the jaw portion, and a cartridge assembly releasably supported on the base portion. A tissue guide member is operably secured relative to the cartridge assembly to facilitate alignment of the cartridge assembly through a firing stroke.

Abstract: A surgical stapling device (10) includes a replaceable cartridge assembly (44) having knife assembly (80) and an anvil assembly (42) including a cutting plate (52). The cutting plate (52) is configured be durable to maintain performance of the stapling device (10) over multiple firings.

Abstract: A surgical stapling device includes a tool assembly having a U-shaped frame, an anvil assembly, and a cartridge assembly. The U-shaped frame has a proximal transverse portion, a longitudinal portion, and a distal transverse portion. The distal transverse portion and the proximal transverse of the U-shaped frame and the cartridge assembly have a common shape including a first linear portion defining a first axis, a second linear portion defining a second axis, and a third linear portion defining a third axis, the first axis being transverse to the longitudinal axis of the elongate body. In embodiments, a first radius of curvature is defined between the first linear portion and the second linear portion such that the first axis and the second axis define an angle ?, and a second radius of curvature is defined between the second linear portion and the third linear portion such that the second axis and the third axis define an angle ?.

Abstract: Palbociclib compositions with improved solubility and bioavailability, methods of their preparation, and methods of treating cancers using the compositions are disclosed.

Abstract: The present invention relates to an amorphous form of Idelalisib and its methods of preparation. Using a Cu-K? radiation, the X-ray powder diffraction (XRPD) pattern does not contain sharp diffraction peaks at a diffraction angle expressed in degrees 2?, and the X-ray powder diffraction pattern is shown in FIG. 1. The present invention also provides a preparation method for the amorphous form of Idelalisib. The amorphous form of Idelalisib of the present invention increases the solubility of Idelalisib and improves bioavailability of the drug product. As compared to the existing crystalline forms of Idelalisib, its solubility increases significantly, which improves body's absorption of the drug and makes it more efficacious in the clinical therapeutic treatment of diseases. Under the stress test conditions, the amorphous material can maintain good physical and chemical stabilities. The preparation method of amorphous Idelalisib according to the present invention is simple to operate and easy to implement.

Abstract: Provided are a pharmaceutical composition of an amorphous vortioxetine or a salt thereof, and a preparation method therefor. The pharmaceutical composition comprises an amorphous vortioxetine or a pharmaceutically acceptable salt thereof and two or more pharmaceutical excipients. The pharmaceutical composition has good stability and dispersity, and enhances the dissolution of vortioxetine or the pharmaceutically acceptable salt thereof, thereby improving the bioavailability of the medicinal formulation and the body absorption of the medicine.

Abstract: The present invention relates to an amorphous form of Idelalisib and its methods of preparation. Using a Cu-K? radiation, the X-ray powder diffraction (XRPD) pattern does not contain sharp diffraction peaks at a diffraction angle expressed in degrees 2?, and the X-ray powder diffraction pattern is shown in FIG. 1. The present invention also provides a preparation method for the amorphous form of Idelalisib. The amorphous form of Idelalisib of the present invention increases the solubility of Idelalisib and improves bioavailability of the drug product. As compared to the existing crystalline forms of Idelalisib, its solubility increases significantly, which improves body's absorption of the drug and makes it more efficacious in the clinical therapeutic treatment of diseases. Under the stress test conditions, the amorphous material can maintain good physical and chemical stabilities. The preparation method of amorphous Idelalisib according to the present invention is simple to operate and easy to implement.

Abstract: A method for preparing rocuronium is disclosed. 2?-(4-Morpholinyl)-16?-(1-pyrrolidinyl)-5?-androstan-3?-ol-17?-acetate is used as a starting material and is directly reacted with 3-bromopropene at ambient temperature to produce rocuronium.

Abstract: Provided is a method for purifying rocuronium bromide, which comprises: formulating crude rocuronium bromide to be purified into an aqueous solution, distilling off excess residue solvents at reduced pressure, absorbing by adding active carbon or silica gel, then filtrating, quick freezing the filtrate into ice, and then lyophilizing to obtain rocuronium bromide.

Abstract: Provided is a method for purifying rocuronium bromide, which comprises: formulating crude rocuronium bromide to be purified into an aqueous solution, distilling off excess residue solvents at reduced pressure, absorbing by adding active carbon or silica gel, then filtrating, quick freezing the filtrate into ice, and then lyophilizing to obtain rocuronium bromide.

Abstract: A method for preparing rocuronium is disclosed. 2?-(4-Morpholinyl)-16?-(1-pyrrolidinyl)-5?-androstan-3?-ol-17?-acetate is used as a starting material and is directly reacted with 3-bromopropene at ambient temperature to produce rocuronium.

Abstract: The present invention is directed to N-[2-[[(diaminomethylene)amino]oxy]ethyl]-3-[(2,2-difluoro-2-phenylethyl)amino]-6-methyl-s-oxo-1(2H)-pyrazineacetamide, pharmaceutical compositions containing said compound and methods of treatment comprising inhibiting a serine protease using said compound. The present invention is further directed to a process for the preparation of the N-[2-[[(diaminomethylene)amino]oxy]ethyl]-3-[(2,2-difluoro-2-phenylethyl)amino]-6-methyl-2-oxo-1(2H)-pyrazineacetamide as a free base. The present invention is further directed to a process for the preparation of pharmaceutically acceptable salts of N-[2-[[(aminoiminomethyl)amino]oxy]ethyl]-3-[(2,2-difluoro-2-phenylethyl)amino]-6-methyl-2-oxo-1(2H)-pyrazineacetamide.

Abstract: The present invention relates generally to the non-enzymatic glycosylation of amyloidogenic proteins and the consequent formation of advanced glycosylation endproducts (AGEs). It has been found that formation of AGE-amyloidogenic proteins can enhance amyloidosis. The invention further relates to compositions and methods for the prevention and treatment of amyloidosis associated with amyloid diseases, particularly neurodegenerative disease and Type II diabetes, and more particularly Alzheimer's disease. In a specific example, aggregation of an amyloidogenic peptide, &bgr;AP, is enhanced by the glycosylation reaction of &bgr;AP to form AGE-&bgr;AP as defined herein. Accordingly, the invention extends to a method for modulating the in vivo aggregation of amyloid polypeptides and associated amyloidosis by controlling the formation and presence of AGE-amyloid polypeptide.